Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2018 Jul 16;8:10746. doi: 10.1038/s41598-018-28792-1

A community-based study on the association between Helicobacter pylori Infection and obesity

Li-Wei Chen 1,2, Sheng-Fong Kuo 2,3, Chih-Hung Chen 3, Cheng-Hung Chien 1,2, Chih-Lang Lin 1,2, Rong-Nan Chien 1,2,
PMCID: PMC6048143  PMID: 30013128

Abstract

Helicobacter pylori (H. pylori) infection can induce chronic inflammation and is associated with insulin resistance, metabolic syndrome and body mass index (BMI, kg/m2) changes. This study aimed to evaluate the association between H. pylori infection and overweight/obesity. This research was a cross-sectional study conducted from March 2014 to November 2016, using data from the three districts in the northeastern region of Taiwan. The inclusion criteria were an age >30 years and the absence of pregnancy. Ultimately, 2686 subjects (1713 women) were included in this study. Among the subjects aged less than 50 years, the subjects with H. pylori infection had higher mean BMI values than those without H. pylori infection (40–49 years: 25.7 ± 4.4 vs. 24.7 ± 3.8, P = 0.025; 30–39 years: 24.9 ± 4.4 vs. 24.0 ± 4.1, P = 0.063). H. pylori infection increased the risk of being obese 2 (BMI ≥30) (odds ratio, OR = 1.836, 95% CI = 1.079–3.125, P = 0.025) with adjustments for demographic factors in subjects aged less than 50 years. In conclusions, subjects with H. pylori infection and age less than 50 years may increase a risk of being obesity (BMI ≥30) compared to those without this type of infection.

Introduction

Overweight or obesity is a worldwide epidemic disease and a public health problem in Taiwan14. The prevalence of overweight in adults is 38.5% (men 48.7%, women 28.3%) based on the Taiwan criteria (body mass index, BMI ≥ 24 kg/m2)3,4. Obesity-related comorbidities, such as diabetes mellitus and hypertension, are a public health economic burden in Taiwan5. Excessive caloric intake and decreased physical activity are the main reasons for the increasing prevalence of obesity6. Recently, gut microbiota has been reported to have an important role in the development of obesity7,8. Helicobacter pylori (H. pylori) is a gram-negative microorganism found in the human stomach. Chronic infection with H. pylori will induce an immune response and result in local gastritis or a systemic response9,10. In recent studies, H. pylori was also found to be associated with some extradigestive diseases, such as insulin resistance, metabolic syndrome and obesity1113. The mechanism associating H. pylori infection and obesity may be related to H. pylori infection-related gastritis or peptic ulcer, immunological cytokines and leptin1418. In clinical observations, H. pylori infection-related gastritis or peptic ulcers have been found to lead to dyspepsia and poor appetite. Patients gain weight following successful H. pylori eradication1921. Tumor necrosis factor-α (TNF-α) is a key mediator of inflammation that is involved in the development of obesity-related insulin resistance22. Leptin is an adipokine and might regulate body weight via decreased appetite and food intake23. Gastric inflammation is highest with cytotoxin-associated gene A (cagA) strains of H. pylori24,25. The prevalence of H. pylori infection is approximately 50–60% in people aged 50 years old, and most (99%) of the H. pylori infection strains are cagA-positive strains in Taiwan26. H. pylori infection can induce changes in gastric mucosal leptin and TNF-α levels, which influence body weight changes10,14,16,27,28. Recent cross sectional studies have reported conflicting results that demonstrate an association between H. pylori infection and BMI13,2934. Most of these association studies lacked adjustments for confounding factors, such as socioeconomic class, education status, jobs, and mental or psychological evaluations, which are associated with BMI. It is necessary accurately adjust for these potential confounders to evaluate the association between H. pylori infection and BMI. We hypothesized that colonization with H. pylori is associated with a change in BMI due to chronic inflammation and insulin resistance and that cytokines (TNF-α and C reactive protein) and adipokines (adiponectin and leptin) are involved. Most patients get H. pylori infections during childhood, the inflammatory influences of H. pylori infection on body weight may be different between patients in the young age (early life) and in the old age (late life)35. This study aimed to evaluate the association between H. pylori infection and BMI using data from three districts in the northeast region of Taiwan. Data including age, inflammatory cytokine and adipokine levels as well as detailed demographic data (socioeconomic status, education, job, mental or psychological evaluation scores) were included in the analysis.

Results

A total of 2723 subjects were enrolled. Eighty-two subjects were excluded because their BMIs were less than 18.5 kg/m2 (underweight or thin). Thirty-seven subjects were excluded because they had underling diseases or took drugs that would interfere with the H. pylori test or the accuracy of the BMI calculation. Eighteen subjects had taken proton pump inhibitors, antibiotics or H. pylori eradication medications within one month, no subjects were taking body weight remodeling drugs (i.e. Xenical), four subjects were taking steroids, six subjects were on hormone therapy, six subjects had underlying diseases or thyroid disorders, and three subjects had underlying malignancies. Ultimately 2604 subjects (1713 women) were included in this study (Fig. 1). These subjects were divided into the following 4 groups by BMI stratification: 1098 subjects in the normal weight group (18.5 ≤ BMI < 24), 818 (31.4%) in the overweight group (24 ≤ BMI < 27), 446 (17.1%) in the obese 1 group (27 ≤ BMI < 30), and 242 (9.3%) in the obese 2 group (BMI ≥ 30). The demographic and characteristic data are listed in Table 1. More than half (57.8%) of the subjects were overweight or obese (BMI ≥ 24). Subjects in the overweight, obese 1 and obese 2 groups were more likely to be male than those in the normal weight group (41%, 43.5%, 47.1%, respectively vs. 28.1%, P < 0.001). The prevalence of DM, hyperlipidemia, HTN and metabolic syndrome were higher among the overweight and obese subjects than those of normal weight subjects. The overweight and obese subjects had higher mean HOMA-IR, HS-CRP, leptin, TNF-α, and WBC values and lower mean adiponectin values than those with normal weight. Figure 2 reveals that prevalence of H. pylori infection in the normal, overweight, obese 1 and obese 2 subjects as classified according to Taiwan’s criteria and the WHO Asian criteria for overweight or obesity. The blue bars (Taiwan criteria) reveal that the prevalence of H. pylori infection in the normal (18.5 ≤ BMI < 24), overweight (24 ≤ BMI < 27), obese 1 (27 ≤ BMI < 30) and obese 2 (BMI ≥ 30) subjects were 50.1%, 56.5%, 54.0% and 54.5%, respectively (P for trend = 0.044). The red bars (Asian criteria) indicated that the prevalence of H. pylori infection in the normal (18.5 ≤ BMI < 23), overweight (23 ≤ BMI < 27.5), obese 1 (27.5 ≤ BMI < 30) and obese 2 (BMI ≥ 30) subjects were 49.0%, 55.4%, 54.4% and 54.4%, respectively (P for trend = 0.034). Figure 3 illustrates that the mean BMI values of the subjects with H. pylori infection (red line) and without H. pylori infection (blue line) as stratified by age. In the age periods of 40–49 and 30–39 years, the subjects with H. pylori infection had higher mean BMI values than those without H. pylori infection (40–49 years: 25.7 ± 4.4 vs. 24.7 ± 3.8, P = 0.025; 30–39 years: 24.9 ± 4.4 vs. 24.0 ± 4.1, P = 0.063). Among the subjects aged more than 50 years, there were no significant differences in the mean BMIs between the subjects with and without H. pylori infection in any age period.

Figure 1.

Figure 1

Flow diagram.

Table 1.

Demography and Characteristics of Subjects by Body Mass Index Stratification.

Classification Normal Overweight Obese (1) Obese (2) P value
18.5 ≤ BMI < 24 24 ≤ BMI < 27 27 ≤ BMI < 30 BMI ≥ 30
Number (%) 1098(42.2) 818(31.4) 446(17.1) 242(9.3)
Mean age 56.1 ± 14.0 58.7 ± 13.2 58.9 ± 12.5 55.7 ± 13.6 <0.001
Age stratification
  30–39 180(16.4) 85(10.4) 40(9.0) 36(14.9) <0.001
  40–49 165(15.0) 98(12.0) 60(13.5) 44(18.2)
  50–59 293(26.7) 220(26.9) 118(26.5) 55(22.7)
  60–69 279(25.4) 247(30.2) 139(31.2) 67(27.7)
  70–79 125(11.4) 128(15.6) 70(15.7) 35(14.5)
  ≥80 56(5.1) 40(4.9) 19(4.3) 5(2.1)
Gender
  Male 317(28.9) 335(41.0) 194(43.5) 114(47.1) <0.001
  Female 781(71.1) 483(59.0) 252(56.5) 128(52.9) <0.001
H. pylori 550(50.1) 462(56.5) 241(54.0) 132(54.5) 0.044
DM 109(9.9) 134(16.4) 120(26.9) 72(29.8) <0.001
Waist 74.5 ± 6.4 83.1 ± 6.3 90.0 ± 6.1 97.8 ± 8.2 <0.001
Systolic blood pressure 126.3 ± 19.3 133.0 ± 18.0 137.1 ± 18.3 141.6 ± 16.0 <0.001
Diastolic blood pressure 75.8 ± 11.6 78.9 ± 11.1 81.5 ± 11.4 84.9 ± 10.9 <0.001
FBG 99.2 ± 25.9 103.4 ± 24.2 110.4 ± 33.2 115.9 ± 45.0 <0.001
TG 100.9 ± 102.2 135.6 ± 103.7 150.3 ± 112.8 153.1 ± 93.1 <0.001
HDL 61.1 ± 15.2 54.0 ± 13.7 51.1 ± 12.1 48.0 ± 11.4 <0.001
Metabolic syndrome 100(9.1) 243(29.7) 239(53.6) 170(70.2) <0.001
Dyslipidemia 905(82.6) 735(90.0) 398(89.2) 219(90.5) <0.001
HOMA-IR value 1.5 ± 1.8 2.2 ± 2.0 3.1 ± 2.7 4.5 ± 5.6 <0.001
HS-CRP 2.0 ± 5.8 2.4 ± 6.0 2.6 ± 5.2 3.6 ± 5.5 0.002
Adiponectin 9.5 ± 5.3 7.7 ± 4.8 6.2 ± 3.7 6.6 ± 4.8 <0.001
Leptin 8.6 ± 5.6 11.4 ± 7.0 13.4 ± 7.7 16.8 ± 8.8 <0.001
TNF-α 7.4 ± 4.1 7.5 ± 4.2 8.9 ± 11.3 8.5 ± 6.7 0.008
WBC 5.7 ± 1.8 6.2 ± 1.7 6.4 ± 1.7 6.7 ± 1.8 <0.001
SF-36
  PCS 52.7 ± 7.9 52.1 ± 8.0 50.8 ± 8.7 49.5 ± 9.1 <0.001
  MCS 49.6 ± 9.5 50.1 ± 10.0 51.4 ± 9.7 52.2 ± 9.5 <0.001
Marriage status <0.001
  Unmarried 102(9.3) 44(5.4) 17(3.8) 26(10.7)
  Married 810(73.8) 653(79.8) 356(79.8) 188(77.7)
  Divorce or Widowed 156(14.2) 102(12.5) 63(14.1) 26(10.7)
  Missing 30(2.7) 19(2.3) 10(2.2) 2(0.8)
Alcohol 39(3.6) 43(5.3) 19(4.3) 10(4.1) 0.341
Cigarette smoking 0.007
  Never 836(76.1) 585(71.5) 308(69.1) 167(69.0)
  Former smoker 104(9.5) 106(13.0) 71(15.9) 37(15.3)
  Current smoker 158(14.4) 127(15.5) 67(15.0) 38(15.7)

BMI = body mass index, DM = diabetic mellitus, HOMA-IR = homeostasis model assessment of insulin resistance, HS-CRP = high-sensitivity C reactive protein, TNF-α = Tumor necrosis factor alpha, WBC = white blood cell, SF-36 = short form 36, PCS = physical component summary, MCS = mental component summary,

data presented as mean ± standard deviation.

Figure 2.

Figure 2

The prevalence of current H. pylori infection in normal, overweight and obese subjects according to Taiwan and Asian BMI criteria. The blue bars (Taiwan criteria) indicate the prevalence of H. pylori infection in normal (18.5 ≤ BMI < 24), overweight (24 ≤ BMI < 27), obese 1 (27 ≤ BMI < 30) and obese 2 (BMI ≥ 30, WHO criteria) subjects (P for trend = 0.034). The red bars (Asian criteria) indicate the prevalence of H. pylori infection in normal (18.5 ≤ BMI < 23), overweight (23 ≤ BMI <27.5), obese (27.5 ≤ BMI < 30), and morbidly obese (BMI ≥ 30) subjects (P for trend = 0.044).

Figure 3.

Figure 3

The mean BMI values of the subjects with and without H. pylori infection for every age period.

Table 2 reveals the correlations of the category factors, such as demographic variables, lifestyle variables, underlying disease variables, laboratory variables, and physical/psychological score variables, with BMI level and H. pylori infection. BMI level was positively correlated with demographic factors (age, male and marriage), underlying diseases (DM, hypertension and dyslipidemia), the mental component summary (MCS) score from the SF-36, and laboratory factors (leptin, TNF-α, HS-CRP, HOMA-IR and WBC count). BMI was negatively correlated with the physical component summary (PCS) from the SF-36 and adiponectin value. H. pylori infection was positively correlated with age, DM, the MCS score from the SF-36 and WBC. H. pylori infection was negatively correlated with marriage status. The statistically significance factors in the correlation analyses for both BMI level and H. pylori infection were entered into logistical regression analyses as potential confounding factors. To evaluate the association between H. pylori infection and the BMI stratification, we estimated the odds ratios for being overweight or obese according to H. pylori infection status using logistic regression analyses with adjustments for confounding factors and using the control subjects of normal weight (Table 3).Compared with the subjects of normal weight, H. pylori infection increased the risk of being overweight (OR = 1.226, 95% confidence interval = 1.015–1.480, P = 0.034) with adjustments for demographic factors (age, gender and marriage status). A subgroup analysis was performed according to the age of subjects (less or not less than 50 years). Among subjects aged less than 50 years, the adjusted OR for being obese 2 (BMI ≥ 30) was 1.836 (95% CI = 1.079–3.125, P = 0.025) for the subjects with H. pylori infection compared with the subjects without this infection with adjustments for confounding factors.

Table 2.

Correlation between multivariable, BMI or H. pylori infection.

Variable BMI level H. pylori
Demographic variables
Age 0.058* 0.165*
Gender 0.145* 0.010
Marriage status 0.103* 0.099*
Underlying disease
DM 0.195* 0.041*
Hypertension 0.251* 0.033
Dyslipidemia 0.106* 0.034
Physical/mental score
SF-36
  PCS −0.115* −0.017
  MCS 0.099* 0.064*
Laboratory factors
Adiponectin −0.282* 0.002
Leptin 0.322* 0.006
TNF-α 0.077* 0.047
HS-CRP 0.271* −0.001
HOMA-IR 0.505* 0.006
WBC 0.212* 0.048*

Phi coefficient analysis for category data (H. pylori, gender, DM, HTN, dyslipidemia) and Spearman’s coefficient rho for rank correlation (BMI level) and Pearson’s correlation coefficient for continuous data (age, PCS, MCS, HS-CRP, TNF-α, adiponectin, leptin, HOMA-IR, WBC). *P < 0.05.

Table 3.

The Odds ratio of being overweight or obese in subjects with H. pylori infection than normal control.

Adjust
Confounding factors
Adjusted OR (95% CI) of being overweight or obese.
Normal control: normal weight
All subjects overweight vs. normal P-value Obese (1) vs. normal P-value Obese (2) vs. normal P-value
Demographic variables 1.226(1.015–1.480) 0.034 1.113(0.886–1.398) 0.357 1.212(0.909–1.614) 0.190
+Underlying disease 1.228(1.016–1.483) 0.033 1.111(0.883–1.400) 0.369 1.209(0.904–1.616) 0.201
+Physical and psychological 1.227(1.015–1.482) 0.034 1.100(0.873–1.386) 0.418 1.185(0.886–1.587) 0.253
+Laboratory variables 1.189(0.983–1.438) 0.075 1.045(0.827–1.319) 0.713 1.133(0.845–1.521) 0.404
Subjects aged <50 years
Demographic variables 1.396(0.948–2.056) 0.091 1.085(0.670–1.758) 0.739 1.836(1.079–3.125) 0.025
+Underlying disease 1.404(0.953–2.068) 0.086 1.056(0.649–1.719) 0.826 1.799(1.051–3.080) 0.032
+Physical and psychological 1.385(0.940–2.042) 0.857 1.046(0.643–1.702) 0.857 1.792(1.044–3.076) 0.034
+Laboratory variables 1.380(0.933–2.040) 0.107 1.017(0.619–1.671) 0.946 1.759(1.019–3.039) 0.043
Subjects aged ≥50 years
Demographic variables 1.143(0.919–1.421) 0.229 1.061(0.816–1.378) 0.659 0.999(0.708–1.409) 0.994
+Underlying disease 1.144(0.919–1.423) 0.229 1.061(0.814–1.384) 0.660 1.000(0.705–1.418) 0.999
+Physical and psychological 1.148(0.923–1.429) 0.215 1.050(0.805–1.370) 0.719 0.983(0.692–1.395) 0.921
+Laboratory variables 1.098(0.880–1.369) 0.409 0.987(0.755–1.291) 0.924 0.920(0.647–1.310) 0.645

The confounding factors were adjusted by a stepwise method: first demographic variable, second add underlying disease on demographic variable, third add physical and psychological score variable on demographic plus underlying diseases, finally including all confounding factors.

OR = odds ratio, CI = 95% confidence interval.

Demographic variables: age, sex, marriage.

Underlying disease variables: DM.

Physical and psychological score variables: MCS.

Laboratory variables: WBC.

Control group: normal weight BMI 18.5–24 kg/m2.

Discussion

In the current study, more than half of the subjects were overweight or obese among those aged 50 years or older. The prevalence of overweight or obesity (BMI ≥ 24) was 56.2%, and the mean age was 55.2 years old in this group. As in a previous report, the current study found that most of the overweight or obese people were male, and they had higher prevalence of insulin resistance or diabetic mellitus, dyslipidemia and metabolic syndrome5,6.

The associations between H. pylori infection and overweight/obesity are still under debate (Table 4). The reasons for inconclusive results are multifactorial and include different subject sources (e.g., young, middle-aged or elderly), H. pylori detection methods (e.g., serum antibody, urea breath test or histology) and BMI criteria for the normal, overweight and obese categories. The majority of the studies did not exclude the underweight (thin) with BMIs < 18.5 from the normal control group.

Table 4.

Recent studies of the association between H. pylori infection and overweight/obese.

Year Author, nation, subjects source Number
Mean age (year)
H. pylori detected method BMI (kg/m2) criteria H. pylori and obese association
OR (95%CI)
Refs
2000 Rosenstock, Danmark,
Community
2913
44.6
Serum IgG Ab Upper quartile ≥26.8 Positive
1.6 (1.1–2.4)
49
2009 Arslan,
Turkey,
Hospital
214
24.3
Serum IgG Ab Obese ≥30 Positive
2.11 (1.49–3.00)
33
2007 Kopacova, Czech,
Community
2436
40.6
UBT Overweight ≥25
Obese ≥30
Positive
overweight
1.31 (1.05–1.64)
obese
1.25 (0.99–1.57)
36
2008 Thjodleifsson, Sweden,
Community
985
42
Serum IgG Ab Overweight >25 Positive
1.86 (1.34–2.60)
37
2014 Yang,
Taiwan,
Hospital
324
67.6
Histology Obese ≥27 Positive in elderly,
1.89 (1.04–3.45)
38
2015 Zhang,
China,
Hospital
2050
52.2
UBT Overweight ≥23
Obese ≥27.5
Positive
Overweight 1.25(1.00–1.53)
Obese 1.28(1.00–1.61)
34
2001 Kawano,
Japan,
Hospital
155
44.2
Serum IgG Ab BMI value No association 39
2002 Kyriazanos, Greece,
Hospital
224
22.8
Serum IgG Ab BMI ≥25 No association 29
2003 Archimandritis, Greece,
Hospital
200
48
Serum IgG Ab Overweight ≥24
Obese ≥27
No association 40
2005 Cho,
USA,
Community
7003
45.2
Serum IgG Ab Overweight ≥25 No association 32
2005 Ioannou,
USA,
Community
6724
46.7
Serum IgG Ab Obese ≥30 No association 31
2005 Wu,
Taiwan,
Hospital
1097
31.9
Serum IgG Ab Morbid obese ≥35 Inverse relationship 13
2007 Mendez-Sanchez Mexico,
Hospital
283
46.4
Histology BMI value No association 41

Use China BMI criteria for obese (≥28) OR = 1.14 (0.89–1.47) (P > 0.05) morbid obesity (BMI ≥ 35) vs. normal weight (BMI < 20).

An analysis of an age- and sex-stratified cross section of the Danish population (n = 2913) found that subjects in the upper fourth of the BMI distribution were slightly more likely to be H. pylori-seropositive (OR adjusted for socioeconomic factors 1.6, 95% CI: 1.1–2.4)36. Arslan et al. also found a higher H. pylori infection rate among a young obese group of Turks (mean 24.3 years) compared to a control group (25.5 years; 57.2% vs. 27.0%) and a significant association between obesity and serum antibody positivity for H. pylori (OR = 2.11, 95% CI = 1.49–3.00, P < 0.001)33. Two studies by Kopácová et al.37 of 2,436 Czech people (mean 40.6 years) and Thjodleifsson et al.38 of 985 Swedish subjects (mean 42 years) also found significant associations between H. pylori infection and obesity. Recently, two studies by Yang et al.39 and Zhang et al.34 from Taiwan and China, respectively, also reported a higher prevalence of H. pylori infection among overweight and obese subjects than among those of normal weight. Zhang et al. reported a trend of increasing H. pylori infection rates among normal, overweight and obese subjects (37.36%, 41.88%, 45.77% respectively; P for trend = 0.006)34.

However, other cross-sectional studies have found no association between H. pylori colonization and the risk of obesity29,31,32,4043. Kawano et al.40, Kyriazanos et al.29, and Archimandritis et al.41 reported that H. pylori infection is not related to BMI in Japanese and Greek subjects. Later USA studies by Ioannou et al.31 and Cho et al.32 reported no relationship between H. pylori and overweight/obesity.

The P value (0.044) for the difference in the incidence of H. pylori infection was P value for the trend of the 4 study groups, including normal, overweight, obese 1 and obese 2 by Taiwan’s criteria. Similarly, the P value was 0.034 by Asian’s criteria. The reason for the marginal difference of H. pylori infection among these 4 groups was the close H. pylori infection rates between the groups of overweight (56.5%), obese 1 (54%) and obese 2 (54.5%). When we compare the H. pylori infection rate between normal group (50.1%) and overweight group (56.5%) separately, the difference in the incidence of H. pylori infection is very significant (P < 0.01). Although the H. pylori rates in obese1 (54.0%) and obese 2 (54.5%) were higher than the rate in normal group (50.1%), the difference was not significant by Chi-square statistic (P > 0.05). The reason may be due to relatively small number in the obese 1 and obese 2 (type 2 error). The other explanation is age distribution. If we classified the age with 10 years interval, we find the most different mean BMI value between subjects with or without H. pylori infection was in age interval 40–50 years old. The mean BMI of subjects aged within 40–50 years and H. pylori infection was higher than those without this infection (25.7 ± 4.4 vs. 24.7 ± 3.8, P = 0.025). If we just compare the H. pylori infection rates without age classification between these 4 groups, the incidences of H. pylori among these 4 groups were only marginal significance. If we divided the subjects by aged less than or more than 50 years old, the difference of H. pylori infection rate among these 4 groups was more significant in subjects aged less than 50 years. In the current study, we found an association between H. pylori infection and overweight after adjusting for certain confounding factors including age and sex. Moreover, when analyzing subjects aged less than 50 years, H. pylori infection was associated with obese2 (BMI ≥ 30 kg/m2).This is consistent with our previous finding that H. pylori infection increased insulin resistance and metabolic syndrome in residents younger than 50 years old12. Present study further disclosed H. pylori infection increasing the risk of being obese2 (BMI ≥ 30) than control group in the subjects aged less than 50 years. Hence, the influence of H. pylori infection on BMI maybe more prominent in subjects aged less than 50 years, when H. pylori infection is active and showing more influences on insulin resistance11,12,44.

One Taiwanese study from Wu et al. found that the H. pylori frequency is lower among the morbidly obese than normal control subjects (43.7% in 414 subjects with BMIs ≥ 35 vs. 60.0% in 683 subjects with BMIs < 25). These authors found an inverse relationship between H. pylori and BMI and volunteered the hypothesis that H. pylori could prevent progression to obesity15. Other studies are conflicting and have reported weight gain (increased BMI) after successful H. pylori eradication1921,42. In the current study, a subgroup analysis of the 42 obese subjects (mean age 52.1 years) with BMIs ≥ 35 kg/m2 was also performed, and the H. pylori infection rate was 59.5%. This infection rate was similar to the rates in the overweight (56.5%) and obese (27 ≤ BMI < 35, 53.90%) subjects but higher than the rate in the normal weight subjects (50.1%). The reasons for the different findings regarding the H. pylori infection rates among morbid obesity subjects (BMI ≥ 35) between Wu’s study and the current study are multifactorial and include the subject source (hospitalized patients vs. community people), the H. pylori detecting method (serum antibody test vs. UBT) and different BMI cutoff points for normal controls (BMI ≤ 25 vs. 18.5 ≤ BMI < 24).

The additional information provided by this study is that the effect of H. pylori on obesity may be different between young subjects (aged less than 50) and older subjects. Because most subjects get H. pylori infection in young age, the inflammatory responses for H. pylori infection may be more predominant in this period9,10,35. However, old subjects have more comorbidity, which results into more inflammatory responses in the whole body, will attenuate or dilute the effect of H. pylori infection on obesity, insulin resistance or metabolic syndrome.

There are some limitations in the current study. First, this was a cross-sectional study based on community health screening data, so selection bias cannot be excluded. Second, esophagogastroduodenoscopy was not performed for subjects with H. pylori infection. Some people with H. pylori infection experienced atrophic gastritis, dyspepsia and weight loss, but other people with H. pylori infection did not experience appetite loss or weight change. The causality of H. pylori infection-induced weight change could not be determined in this study. Third, some results, such as daily exercise time or medicine use, were from questionnaires but not from real tests or medical records. Under or overestimated data would be collected due to unsure memory of subjects. Four, the result of current study could not be generalized beyond our study population and area, because the life pattern or food of our subjects may be different from the residents of other areas.

In conclusion, subjects with H. pylori infection and age less than 50 years old may increase a risk of being obesity than those without this infection.

Methods

This study originated from a community-based survey for metabolic syndrome and H. pylori infection. It was performed in the northeastern region of Taiwan, which included the Wanli, Ruifang and Anle districts, from March 2014 to November 2016. The inclusion criteria were an age ≥ 30 years and the absence of pregnancy. The exclusion criteria were conditions that would interfere with H. pylori tests or BMI calculation accuracy. Participants were excluded if they were currently or had recently (within one month) received medicines for H. pylori eradication, body weight remodeling (i.e. Xenical), rheumatoid arthritis or autoimmune diseases (i.e., steroid or immunosuppressant treatment), thyroid disorder and malignancy. A standardized questionnaire was administered to all participants by a trained team of interviewers. The items in the questionnaire involved comprehensive alcohol consumption (amount and duration), smoking and betel nut chewing status, and physical activity (the SF36 health survey and daily activity time). All participants received a demographic survey, a physical examination, a 13C urea breath test (UBT) for detecting H. pylori infection, and blood tests. The demographic survey assessed the family history and the medical history of systemic diseases, such as diabetes mellitus (DM), hypertension, hyperlipidemia, rheumatoid arthritis, autoimmune diseases and malignancy. A survey of medication history included proton pump inhibitor therapy, H. pylori eradication, antibiotics received within one month, hormone therapy, and steroid or immunosuppressant treatment. The physical examination included measurements of basic vital signs (body temperature, respiratory rate, heart rate, and blood pressure), body weight, body height, and waist girth (circumference). Waist girth was measured at the midline between the lowest margin of the subcostal rib and the upper margin of the iliac crest.

The study was conformed to the ethical guidelines of the Declaration of Helsinki, and was performed with the approval of the ethical committee of the Keelung Chang Gung Memorial Hospital. The Institutional Review Board of the Chang-Gung Memorial Hospital approved this research (IRB No: 103-3886C). All participants agreed to join the study and signed an informed consent form before enrollment into the study.

Body mass index (BMI)

The BMI was calculated as the weight (kg) divided by squared height (m), and the result was recorded in kg/m2. The cutoff points for BMI were adopted as suggested by the health promotion administration of the Ministry of Health and Welfare in Taiwan and included normal (18.5 ≤ BMI < 24), overweight (24 ≤ BMI < 27), and obese (BMI ≥ 27) categories5. According to the principal cutoff points for obesity from the WHO, a further analysis of the obese subjects was performed by dividing the obese subjects into obese 1 (27 ≤ BMI < 30) and obese 2 (BMI ≥ 30) groups. Another BMI classification from the WHO Expert Consultation for Asians was also used for the analysis in which normal weight was defined as 18.5 ≤ BMI < 23 kg/m2, overweight was defined as 23 ≤ BMI < 27.5 kg/m2 and obesity was defined as BMI ≥ 27.5 kg/m2 45.

Metabolic syndrome (MS)

A race-specific waist circumference threshold was applied to prevent a discrepancy in MS prevalence according to the NCEP ATP III criteria46.

Urea breath test (UBT)

H. pylori infection was detected with the Proto Pylori kit (Isodiagnostika, Canada), which contains 75 mg of 13C-urea and additives. The results are expressed as delta over baseline (DOB) based on the comparison of two breath samples that were obtained within a 30-minute interval and analyzed by gas chromatography/isotope ratio mass spectrometry. A local validation test with a DOB cut-off value of 3.5 yielded a sensitivity of 96% (95% confidence interval [CI]: 93%–99%) and a specificity of 98% (95% CI: 93%–102%) according to the manufacturer’s reference.

Adiponectin and leptin

Serum adiponectin and leptin levels were examined with two commercial kits (Human Total Adiponectin/Acrp30, BioVendor Research and Diagnostic system, Minneapolis, MN; Human Leptin ELISA, Clinical Range, BioVendor Laboratory Medicine, Karasek, Czech Republic) according to the manufacturers’ instructions.

Tumor necrosis factor alpha (TNF-α)

A quantitative sandwich enzyme immunoassay technique was used for the TNF-α assay according to the manufacturer’s instructions (Immunite 1000 LKNF1, Siemens Medical Solutions Diagnostics, Llanberis, UK).

Homeostasis model assessment of insulin resistance (HOMA-IR)

The HOMA-IR score was calculated according to the following formula:

fastingplasmainsulin(mU/L)×fastingplasmaglucose(mmol/L)/22.5.

A higher HOMA-IR score indicates a greater tendency for insulin resistance (i.e., a lower insulin sensitivity)47.

Short form-36 (SF-36)

The Chinese version of the SF-36 questionnaire was applied for the quality of life survey48,49. A lower score indicates greater disability, and a higher score indicates less disability. Two aggregate summary measures, i.e., the physical component summary (PCS) and the mental component summary (MCS), were also analyzed.

Statistical methods

For continuous variables, the values are expressed as the means and the standard deviations (SDs). T-test was applied for comparing the mean values of two samples. One-way ANOVA was used for comparing the mean values of multiple samples. Categorical data were analyzed with the chi-square test or the Fisher exact test as appropriate. All statistical tests were 2-tailed. A P-value of < 0.05 was considered to indicate a statistically significant difference. Correlation coefficients, such as the Pearson, phi and Spearman rho correlation coefficients were chosen. The phi coefficient analysis was utilized for binary category data (i.e. H. pylori), the Spearman rho coefficient was used for rank correlations (i.e. normal weight, overweight, obese 1 and obese 2) and the Pearson correlation coefficient was used for continuous data (i.e. HS-CRP, TNF-α, adiponectin, leptin). The statistical analyses were performed using SPSS (version 16.0, SPSS Inc., Chicago, IL) for Windows.

Ethical Adherence

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board of the Chang-Gung Memorial Hospital approved this research (IRB No: 103-3886C). All participants agreed to the study conditions and provided informed consent before the enrollment in this study.

Acknowledgements

We acknowledge Dr. Kuan-Fu Chen and Miss Yu-Chiau Shyu for help in collecting serum samples from the core unit of the community medicine research center. This study was supported by grants from Chang-Gung Memorial Hospital (No. CMRPG2B0123 and CMRPG2B0173). The authors have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Author Contributions

L.W.C., C.H.C., S.F.K. and R.N.C. provided study concept and design. L.W.C., C.H.C. and C.L.L. collected data. L.W.C. performed data analysis and interpretation. L.W.C. and R.N.C. wrote the manuscript. All of the authors read and approved the final manuscript.

Competing Interests

The authors declare no competing interests.

Footnotes

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Stein CJ, Colditz GA. The epidemic of obesity. J. Clin. Endocrinol. Metab. 2004;89:2522–2525. doi: 10.1210/jc.2004-0288. [DOI] [PubMed] [Google Scholar]
  • 2.Arroyo-Johnson C, Mincey KD. Obesity epidemiology worldwide. Gastroenterol. Clin. North. Am. 2016;45:571–579. doi: 10.1016/j.gtc.2016.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chu NF. Prevalence of obesity in Taiwan. Obes. Rev. 2005;6:271–274. doi: 10.1111/j.1467-789X.2005.00175.x. [DOI] [PubMed] [Google Scholar]
  • 4.Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J. Formos. Med. Assoc. 2006;105:626–635. doi: 10.1016/S0929-6646(09)60161-3. [DOI] [PubMed] [Google Scholar]
  • 5.Chu NF, Wang SC, Chang HY, Wu DM. Medical services utilization and expenditure of obesity-related disorders in Taiwanese adults. Value Health. 2010;13:829–836. doi: 10.1111/j.1524-4733.2010.00776.x. [DOI] [PubMed] [Google Scholar]
  • 6.Damcott CM, Sack P, Shuldiner AR. The genetics of obesity. Endocrinol. Metab. Clin. North. Am. 2003;32:761–786. doi: 10.1016/S0889-8529(03)00076-8. [DOI] [PubMed] [Google Scholar]
  • 7.Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–249. doi: 10.1038/nature11552. [DOI] [PubMed] [Google Scholar]
  • 8.Kumari M, Kozyrskyj A. Gut microbial metabolism defines host metabolism: an emerging perspective in obesity and allergic inflammation. Obes. Rev. 2017;18:18–31. doi: 10.1111/obr.12484. [DOI] [PubMed] [Google Scholar]
  • 9.Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 2006;19:449–490. doi: 10.1128/CMR.00054-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment. Pharmacol. Ther. 1996;10:29–37. doi: 10.1046/j.1365-2036.1996.22164003.x. [DOI] [PubMed] [Google Scholar]
  • 11.Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16:79–88. doi: 10.1111/j.1523-5378.2011.00822.x. [DOI] [PubMed] [Google Scholar]
  • 12.Chen LW, et al. Helicobacter pylori infection increases insulin resistance and metabolic syndrome in residents younger than 50 years old: a community-based study. PLoS One. 2015;10:e0128671. doi: 10.1371/journal.pone.0128671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch. Intern. Med. 2005;165:1552–1555. doi: 10.1001/archinte.165.13.1552. [DOI] [PubMed] [Google Scholar]
  • 14.Noach LA, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. Gastroenterol. 1994;29:425–429. doi: 10.3109/00365529409096833. [DOI] [PubMed] [Google Scholar]
  • 15.Moss SF, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut. 1994;35:1567–1570. doi: 10.1136/gut.35.11.1567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Azuma T, et al. Gastric leptin and Helicobacter pylori infection. Gut. 2001;49:324–329. doi: 10.1136/gut.49.3.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Thalmaier U, et al. Role of tumor necrosis factor alpha in Helicobacter pylori gastritis in tumor necrosis factor receptor 1-deficient mice. Infect. Immun. 2002;70:3149–3155. doi: 10.1128/IAI.70.6.3149-3155.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91. doi: 10.1126/science.7678183. [DOI] [PubMed] [Google Scholar]
  • 19.Kamada T, et al. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig. Liver Dis. 2005;37:39–43. doi: 10.1016/j.dld.2004.07.017. [DOI] [PubMed] [Google Scholar]
  • 20.Fujiwara Y, et al. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology. 2002;49:1298–1302. [PubMed] [Google Scholar]
  • 21.Lane A, et al. Effect of Helicobacter pylori eradication on body weight: the Bristol Helicobacter Project. Gastroenterology. 2003;124:A622–A623. doi: 10.1016/S0016-5085(03)83155-4. [DOI] [Google Scholar]
  • 22.Peluso I, Palmery M. The relationship between body weight and inflammation: lesson from anti-TNF-alpha antibody therapy. Hum. Immunol. 2016;77:47–53. doi: 10.1016/j.humimm.2015.10.008. [DOI] [PubMed] [Google Scholar]
  • 23.Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology. 1998;115:997–1001. doi: 10.1016/S0016-5085(98)70272-0. [DOI] [PubMed] [Google Scholar]
  • 24.Censini S, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease associated virulence factors. Proc. Nat. Acad. Sci. USA. 1996;93:14648–14653. doi: 10.1073/pnas.93.25.14648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Blaser MJ, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55:2111–2115. [PubMed] [Google Scholar]
  • 26.Lai CH, et al. High prevalence of cagA- and babA2-positive Helicobacter pylori clinical isolates in Taiwan. J. Clin. Microbiol. 2002;40:3860–3862. doi: 10.1128/JCM.40.10.3860-3862.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Breidert M, et al. Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori -associated gastritis. Scand. J. Gastroenterol. 1999;34:954–961. doi: 10.1080/003655299750025039. [DOI] [PubMed] [Google Scholar]
  • 28.Roper J, et al. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J. Clin. Endocrinol. Metab. 2008;93:2350–2357. doi: 10.1210/jc.2007-2057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kyriazanos ID, et al. The incidence of Helicobacter pylori infection is not increased among obese young individuals in Greece. J. Clin. Gastroenterol. 2002;34:541–546. doi: 10.1097/00004836-200205000-00012. [DOI] [PubMed] [Google Scholar]
  • 30.Azuma T, et al. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment. Pharmacol. Ther. 2002;16:240–244. doi: 10.1046/j.1365-2036.16.s2.31.x. [DOI] [PubMed] [Google Scholar]
  • 31.Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment. Pharmacol. Ther. 2005;21:765–772. doi: 10.1111/j.1365-2036.2005.02369.x. [DOI] [PubMed] [Google Scholar]
  • 32.Cho I, et al. Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2005;162:579–584. doi: 10.1093/aje/kwi237. [DOI] [PubMed] [Google Scholar]
  • 33.Arslan E, Atilgan H, Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. Eur. J. Intern. Med. 2009;20:695–697. doi: 10.1016/j.ejim.2009.07.013. [DOI] [PubMed] [Google Scholar]
  • 34.Zhang Y, et al. Association between Helicobacter pylori infection and overweight or obesity in a Chinese population. J. Infect. Dev. Ctries. 2015;9:945–953. doi: 10.3855/jidc.6035. [DOI] [PubMed] [Google Scholar]
  • 35.Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment. Pharmacol. Ther. 1995;9(Suppl 2):33–39. [PubMed] [Google Scholar]
  • 36.Rosenstock SJ, Jorgensen T, Andersen LP, Bonnevie O. Association of Helicobacter pylori infection with lifestyle, chronic disease, body-indices, and age at menarche in Danish adults. Scand. J. Public Health. 2000;28:32–40. doi: 10.1177/140349480002800107. [DOI] [PubMed] [Google Scholar]
  • 37.Kopácová M, et al. Body indices and basic vital signs in Helicobacter pylori positive and negative persons. Eur. J. Epidemiol. 2007;22:67–75. doi: 10.1007/s10654-006-9090-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Thjodleifsson B, et al. Infections and obesity: a multinational epidemiological study. Scand. J. Infect. Dis. 2008;40:381–386. doi: 10.1080/00365540701708293. [DOI] [PubMed] [Google Scholar]
  • 39.Yang GH, et al. Obesity associated with increased risk of gastric Helicobacter pylori infection in an elderly Chinese population. J. Am. Geriatr. Soc. 2014;62:190–192. doi: 10.1111/jgs.12618. [DOI] [PubMed] [Google Scholar]
  • 40.Kawano S, et al. Helicobacter pylori infection does not affect serum leptin concentration and body mass index (BMI) in asymptomatic subjects. J. Gastroenterol. 2001;36:579–580. doi: 10.1007/s005350170064. [DOI] [PubMed] [Google Scholar]
  • 41.Archimandritis AJ, et al. The incidence of Helicobacter pylori is not increased in obese people, but the risk of duodenal ulcer is higher in H. pylori-positive people of high obesity. J. Clin. Gastroenterol. 2003;36:184–185. doi: 10.1097/00004836-200302000-00022. [DOI] [PubMed] [Google Scholar]
  • 42.Mendez-Sanchez N, et al. Effect of Helicobacter pylori infection on gastric ghrelin expression and body weight. Rev. Gastroenterol. Mex. 2007;72:359–364. [PubMed] [Google Scholar]
  • 43.Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment. Pharmacol. Ther. 2002;16:799–806. doi: 10.1046/j.1365-2036.2002.01222.x. [DOI] [PubMed] [Google Scholar]
  • 44.Eshraghian A, et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig. Dis. Sci. 2009;54:1966–1970. doi: 10.1007/s10620-008-0557-7. [DOI] [PubMed] [Google Scholar]
  • 45.WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet363, 157–163 (2004). [DOI] [PubMed]
  • 46.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J.A.M.A. 285, 2486-2497 (2001). [DOI] [PubMed]
  • 47.Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883. [DOI] [PubMed] [Google Scholar]
  • 48.Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002. [DOI] [PubMed] [Google Scholar]
  • 49.Tseng HM, Lu JR, Gandek B. Cultural issues in using the SF-36 health survey in asia: results from taiwan. Health Qual. Life Outcomes. 2003;1:72. doi: 10.1186/1477-7525-1-72. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES